New JP Ultraviolet-Visible and Infrared Reference Spectra Published

Recommendation
Monday, 29 September 2025 14.00 - 17.00 h
In March 2023, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has published the "JP Drafts (March 2023) No.2". In this context, five new Ultraviolet-visible and Infrared reference spectra were published.
The following spectra were made available as PDF files:
- Aripiprazole
- Febuxostat
- Lornoxicam
- Oxaliplatin
- Tolvaptan
New monographs of these and for a few other APIs and tablets have also been published.
The comment period runs from 01 March to 31 May 2023. To submit remarks, a form for comments has to be downloaded and sent by e-mail to the authority after it has been filled in.
Related GMP News
23.07.2025New HPTLC Chapter Proposed for The International Pharmacopoeia
22.07.2025AQCG Organises One-Day Track at PharmaLab 2025
22.07.2025ICH publishes Training Materials on Q2(R2) and Q14
22.07.2025AQCG welcomes two new Board Members
22.07.2025Free Webinar on Sampling and Sample Management: Recording & Q&A Document